Jiebeian (azvudine) / Genuine Biotech - LARVOL DELTA

Azvudine combined with Doxitinib, a potential therapy for EGFRm+ NSCLC (AACR 2026) - P1/2 | "In vivo, the combination achieved superior tumor growth inhibition compared to either monotherapy in the NCI-H1975 (EGFR L858R/T790M) xenograft model.Collectively, these findings suggest that the combination of FNC and Doxitinib represents a promising therapeutic strategy to enhance efficacy and overcome acquired resistance in EGFRm⁺ NSCLC. Based on these preclinical and clinical findings, a phase 1/2 clinical trial will be initiated to evaluate the safety and efficacy of this combination therapy in EGFR-mutant NSCLC patients."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Henan Genuine Biotech Co., Ltd.

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies. (PubMed, Front Med) - "FNC remodels the TME by mitigating immunosuppression and amplifying anti-tumor immunity, offering a promising strategy to augment existing immunotherapies. Further clinical evaluation is warranted to ascertain the translational potential of FNC in diverse oncologic settings."

Journal • Oncology • CALR • CD8 • HMGB1

A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Henan Genuine Biotech Co., Ltd.

New P1 trial • Solid Tumor